TAT
Basic information
Region (hg38): 16:71565660-71577092
Links
Phenotypes
GenCC
Source:
- tyrosinemia type II (Definitive), mode of inheritance: AR
- tyrosinemia type II (Definitive), mode of inheritance: AR
- tyrosinemia type II (Strong), mode of inheritance: AR
- tyrosinemia type II (Strong), mode of inheritance: AR
- tyrosinemia type II (Supportive), mode of inheritance: AR
- tyrosinemia type II (Definitive), mode of inheritance: AR
Clinical Genomic Database
Source:
Condition | Inheritance | Intervention Categories | Intervention/Rationale | Manifestation Categories | References |
---|---|---|---|---|---|
Tyrosinemia, type II | AR | Biochemical | Dietary measures (controlled intake of phenylalanine and tyrosine) can be effective, including as relates to neurocognitive outcome | Biochemical; Dermatologic; Neurologic; Ophthalmologic | 18901242; 33934; 6446465; 1356171; 1357662; 8912606; 12227462; 9544843; 16574453; 16917729; 18945316; 21145993; 21636300 |
ClinVar
This is a list of variants' phenotypes submitted to
- Tyrosinemia type II (12 variants)
Variants pathogenicity by type
Statistics on ClinVar variants can assist in determining whether a specific variant type in the TAT gene is commonly pathogenic or not.
In the table, we include only reliable ClinVar variants with their consequences to MANE Select, Mane Plus Clinical transcripts, or transcripts with TSL equals 1. Click the count to view the source variants.
Warning: slight differences between displayed counts and the number of variants in ClinVar may occur, primarily due to (1) the application of a different transcript and/or consequence by our variant effect predictor or (2) differences in clinical significance: we classify Benign/Likely benign variants as Likely benign and Pathogenic/Likely pathogenic variants as Likely pathogenic.
Variant type | Pathogenic | Likely pathogenic | VUS | Likely benign | Benign | Sum |
---|---|---|---|---|---|---|
synonymous | 153 | 156 | ||||
missense | 47 | 57 | ||||
nonsense | 12 | |||||
start loss | 1 | |||||
frameshift | 15 | 21 | ||||
inframe indel | 0 | |||||
splice donor/acceptor (+/-2bp) | 16 | 18 | ||||
splice region | 1 | 5 | 31 | 37 | ||
non coding | 26 | 86 | 120 | |||
Total | 12 | 45 | 74 | 241 | 13 |
Highest pathogenic variant AF is 0.00000657
Variants in TAT
This is a list of pathogenic ClinVar variants found in the TAT region.
You can filter this list by clicking the number of variants in the Variants pathogenicity by type table.
Position | Type | Phenotype | Significance | ClinVar |
---|---|---|---|---|
16-71566867-TA-T | Hypertyrosinemia | Uncertain significance (Jun 14, 2016) | ||
16-71566868-A-T | Tyrosinemia type II | Benign (Jan 13, 2018) | ||
16-71567078-C-T | Tyrosinemia type II | Uncertain significance (Jan 12, 2018) | ||
16-71567088-C-G | Tyrosinemia type II | Likely benign (Jan 12, 2018) | ||
16-71567089-T-C | Tyrosinemia type II | Uncertain significance (Jan 12, 2018) | ||
16-71567153-A-G | Tyrosinemia type II | Uncertain significance (Jan 13, 2018) | ||
16-71567161-T-C | Tyrosinemia type II | Uncertain significance (Jan 13, 2018) | ||
16-71567281-C-T | Tyrosinemia type II | Likely benign (Jan 12, 2018) | ||
16-71567292-C-T | Tyrosinemia type II | Uncertain significance (Jan 13, 2018) | ||
16-71567331-C-G | Tyrosinemia type II | Likely benign (Jan 12, 2018) | ||
16-71567370-C-T | Tyrosinemia type II | Uncertain significance (Jan 13, 2018) | ||
16-71567402-C-T | Tyrosinemia type II | Uncertain significance (Jan 13, 2018) | ||
16-71567431-A-C | Tyrosinemia type II | Uncertain significance (Jan 13, 2018) | ||
16-71567462-A-G | Tyrosinemia type II | Likely benign (Jan 12, 2018) | ||
16-71567484-C-G | Tyrosinemia type II | Uncertain significance (Jan 13, 2018) | ||
16-71567563-C-T | Tyrosinemia type II | Uncertain significance (Jan 12, 2018) | ||
16-71567665-A-T | Tyrosinemia type II | Uncertain significance (Jan 13, 2018) | ||
16-71567735-C-T | Tyrosinemia type II | Uncertain significance (Apr 27, 2017) | ||
16-71567741-C-A | Tyrosinemia type II | Uncertain significance (Apr 27, 2017) | ||
16-71567747-T-TAG | Hypertyrosinemia | Likely benign (Jun 14, 2016) | ||
16-71567791-TTTC-T | Hypertyrosinemia | Uncertain significance (Jun 14, 2016) | ||
16-71567891-C-G | Tyrosinemia type II | Uncertain significance (Jan 13, 2018) | ||
16-71567892-G-C | Tyrosinemia type II | Uncertain significance (Jan 12, 2018) | ||
16-71567893-A-T | Tyrosinemia type II | Uncertain significance (Jan 13, 2018) | ||
16-71567925-C-T | Tyrosinemia type II | Uncertain significance (Jan 12, 2018) |
GnomAD
Source:
Gene | Type | Bio Type | Transcript | Coding Exons | Length |
---|---|---|---|---|---|
TAT | protein_coding | protein_coding | ENST00000355962 | 11 | 11471 |
pLI Probability LOF Intolerant | pRec Probability LOF Recessive | Individuals with no LOFs | Individuals with Homozygous LOFs | Individuals with Heterozygous LOFs | Defined | p |
---|---|---|---|---|---|---|
0.00690 | 0.992 | 125732 | 0 | 16 | 125748 | 0.0000636 |
Z-Score | Observed | Expected | Observed/Expected | Mutation Rate | Total Possible in Transcript | |
---|---|---|---|---|---|---|
Missense | 0.760 | 220 | 254 | 0.866 | 0.0000147 | 2969 |
Missense in Polyphen | 57 | 83.654 | 0.68138 | 996 | ||
Synonymous | 0.384 | 89 | 93.7 | 0.950 | 0.00000527 | 884 |
Loss of Function | 2.97 | 8 | 23.5 | 0.340 | 0.00000139 | 275 |
LoF frequencies by population
Ethnicity | Sum of pLOFs | p |
---|---|---|
African & African-American | 0.000120 | 0.000120 |
Ashkenazi Jewish | 0.00 | 0.00 |
East Asian | 0.0000544 | 0.0000544 |
Finnish | 0.00 | 0.00 |
European (Non-Finnish) | 0.0000880 | 0.0000879 |
Middle Eastern | 0.0000544 | 0.0000544 |
South Asian | 0.0000653 | 0.0000653 |
Other | 0.00 | 0.00 |
dbNSFP
Source:
- Function
- FUNCTION: Transaminase involved in tyrosine breakdown. Converts tyrosine to p-hydroxyphenylpyruvate. Can catalyze the reverse reaction, using glutamic acid, with 2-oxoglutarate as cosubstrate (in vitro). Has much lower affinity and transaminase activity towards phenylalanine. {ECO:0000269|PubMed:16640556, ECO:0000269|PubMed:7999802}.;
- Disease
- DISEASE: Tyrosinemia 2 (TYRSN2) [MIM:276600]: An inborn error of metabolism characterized by elevations of tyrosine in the blood and urine, and oculocutaneous manifestations. Typical features include palmoplantar keratosis, painful corneal ulcers, and mental retardation. {ECO:0000269|PubMed:1357662}. Note=The disease is caused by mutations affecting the gene represented in this entry.;
- Pathway
- Ubiquinone and other terpenoid-quinone biosynthesis - Homo sapiens (human);Phenylalanine metabolism - Homo sapiens (human);Phenylalanine, tyrosine and tryptophan biosynthesis - Homo sapiens (human);Cysteine and methionine metabolism - Homo sapiens (human);Tyrosine metabolism - Homo sapiens (human);Tyrosinemia, transient, of the newborn;Dopamine beta-hydroxylase deficiency;Disulfiram Action Pathway;Phenylalanine and Tyrosine Metabolism;Tyrosine Metabolism;Alkaptonuria;Monoamine oxidase-a deficiency (MAO-A);Hawkinsinuria;Tyrosinemia Type I;Phenylketonuria;Tyrosinemia Type 3 (TYRO3);Tyrosinemia Type 2 (or Richner-Hanhart syndrome);Methionine De Novo and Salvage Pathway;Amino Acid metabolism;Histidine, lysine, phenylalanine, tyrosine, proline and tryptophan catabolism;Metabolism of amino acids and derivatives;Phenylalanine and tyrosine catabolism;Metabolism;Phenylalanine degradation;tyrosine degradation;4-hydroxybenzoate biosynthesis;Methionine and cysteine metabolism;Tyrosine metabolism;FOXA2 and FOXA3 transcription factor networks
(Consensus)
Recessive Scores
- pRec
- 0.709
Intolerance Scores
- loftool
- 0.244
- rvis_EVS
- -0.56
- rvis_percentile_EVS
- 19.54
Haploinsufficiency Scores
- pHI
- 0.376
- hipred
- Y
- hipred_score
- 0.683
- ghis
- 0.440
Essentials
- essential_gene_CRISPR
- N
- essential_gene_CRISPR2
- N
- essential_gene_gene_trap
- N
- gene_indispensability_pred
- E
- gene_indispensability_score
- 0.999
Gene Damage Prediction
All | Recessive | Dominant | |
---|---|---|---|
Mendelian | Medium | Medium | Medium |
Primary Immunodeficiency | Medium | Medium | Medium |
Cancer | Medium | Medium | Medium |
Mouse Genome Informatics
- Gene name
- Tat
- Phenotype
Gene ontology
- Biological process
- 2-oxoglutarate metabolic process;glutamate metabolic process;L-phenylalanine catabolic process;tyrosine catabolic process;response to oxidative stress;biosynthetic process;response to mercury ion;response to glucocorticoid
- Cellular component
- cellular_component;mitochondrion;cytosol
- Molecular function
- L-tyrosine:2-oxoglutarate aminotransferase activity;protein binding;amino acid binding;pyridoxal phosphate binding